Gout: all 236 studies

Page 1 of 3. Open to participants first (44), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Impact of Dietary Education and Intervention on Gout Patients Receiving Urate-Lowering TherapyEnrolling by invitationNCT07834840Not applicable
• Mazdutide for Weight Management and Gout in Adults With ObesityNot yet recruitingNCT07824895Phase 4
• The Correlation Between Sodium Urate (MSU) Deposition and Coronary Atherosclerosis in Patients With Foot GoutNot yet recruitingNCT07784049
• The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution TimeNot yet recruitingNCT07661030Phase 4
• Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty ArthritisNot yet recruitingNCT07657156
• Probiotic-Uricase Complex Preparation for Improving Uric Acid Metabolism in Patients With HyperuricemiaNot yet recruitingNCT07613164Not applicable
• A Study of IN026 in Participants With Refractory GoutRecruitingNCT07587684Phase 1
• A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout ParticipantsRecruitingNCT07535034Phase 2
• The Orienting StudyRecruitingNCT07504146
• Clinical Trial of BR2251 Tablets for Patients With Primary Gout and HyperuricemiaNot yet recruitingNCT07498647Phase 2
• The Remote Monitoring of Gout Feasibility Study in Primary CareRecruitingNCT07490522Not applicable
• HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-EffectivenessNot yet recruitingNCT07369622Phase 4
• Drug-Drug Interaction Study of ABP-671 in Gout PatientsRecruitingNCT07367971Phase 1
• Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout FlaresRecruitingNCT07346079Phase 4
• Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCTNot yet recruitingNCT07326839Not applicable
• A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)RecruitingNCT07280156Phase 2
• Safety and Efficacy of ABP-745 in Participants With an Acute Gout FlareRecruitingNCT07145229Phase 2
• A Study of Dotinurad Versus Allopurinol in Participants With GoutRecruitingNCT07089875Phase 3
• Developing A Gout Action Plan in Primary Care Setting in SingaporeNot yet recruitingNCT07061587Not applicable
• Clinical Efficacy Trial of Burdock Root Extract in Patients With Asymptomatic HyperuricaemiaRecruitingNCT07002762Not applicable
• Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release TabletsRecruitingNCT06966635Phase 4
• Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In GoutNot yet recruitingNCT06956885Phase 2
• Metformin in Safety and Efficacy in Gouty PatientsRecruitingNCT06924658Phase 2
• Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With GoutRecruitingNCT06887452Not applicable
• Dose Response of Exercise for Arthritis ManagementRecruitingNCT06880653Not applicable
• Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout ArthritisRecruitingNCT06863701Phase 3
• Effect of Dotinurad in Hyperuricemia With HypertensionRecruitingNCT06834230Phase 4
• The Remote Monitoring of Gout StudyEnrolling by invitationNCT06822933Not applicable
• Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2RecruitingNCT06694012
• SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) TrialRecruitingNCT06674109Phase 4
• Time Required to Dissolve Urate DepositsRecruitingNCT06669000
• Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory GoutNot yet recruitingNCT06653686Not applicable
• Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and HyperuricemiaRecruitingNCT06629376Phase 1
• the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or MoreRecruitingNCT06622603Phase 4
• Improving Gout Care After an ED VisitRecruitingNCT06534554Not applicable
• A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.RecruitingNCT06298071Phase 1
• The Effects of Limb Elevation During Gout Flare EpisodesNot yet recruitingNCT06207045Not applicable
• A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutNot yet recruitingNCT06169891Phase 3
• Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic AdjustmentsRecruitingNCT05927688
• Study of Dapansutrile Tablets in Subjects With an Acute Gout FlareRecruitingNCT05658575Phase 2/3
• Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With GoutRecruitingNCT05546593
• Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed AdministrationRecruitingNCT05109936Phase 3
• Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in GoutRecruitingNCT04875702Phase 4
• Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical TrialRecruitingNCT04199325Not applicable
• To Evaluate the Influence of (LUA Probiotics) on Uric AcidCompletedNCT06969469Results posted
• A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory GoutCompletedNCT06229145Phase 4Results posted
• Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With HyperuricemiaCompletedNCT06056570Phase 1/2Results posted
• Phone-Based Based Walk With Ease Program for Adults With ArthritisCompletedNCT05289544Not applicableResults posted
• A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutCompletedNCT05007392Phase 3Results posted
• Medication Adherence Patterns in Rheumatic Diseases: A Behavioral TrialCompletedNCT04776161Not applicableResults posted
• Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase MonotherapyCompletedNCT04772313Phase 4Results posted
• A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)CompletedNCT04762498Phase 4Results posted
• Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs AllopurinolCompletedNCT04746989Results posted
• Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving MethotrexateCompletedNCT04511702Phase 4Results posted
• Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney TransplantCompletedNCT04087720Phase 4Results posted
• Gout in the ED and Improving Research ParticipationCompletedNCT04075903Not applicableResults posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout AttackTerminatedNCT04067492Phase 2Results posted
• Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled GoutCompletedNCT03994731Phase 4Results posted
• A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With HyperuricemiaCompletedNCT03934099Phase 2Results posted
• A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional TherapyCompletedNCT03905512Phase 2Results posted
• Pilot Study Evaluating The Efficacy Of Etanercept In Acute GoutTerminatedNCT03636373Phase 4Results posted
• Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled GoutCompletedNCT03635957Phase 4Results posted
• The Diet Gout TrialCompletedNCT03569020Not applicableResults posted
• Gout Self-Monitoring Aiming to Reach TargetCompletedNCT03274063Not applicableResults posted
• A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal ImpairmentTerminatedNCT03226899Phase 4Results posted
• Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric AcidCompletedNCT02959918Phase 2Results posted
• Denosumab In Addition To Intense Urate-Lowering Therapy for Bone ErosionsCompletedNCT02903446Phase 2Results posted
• Novel Methods for Ascertainment of Gout Flares -A Pilot StudyCompletedNCT02855437Not applicableResults posted
• Virtual Gout ClinicCompletedNCT02790463Not applicableResults posted
• SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO2 StudyCompletedNCT02741700Not applicableResults posted
• CSP594 Comparative Effectiveness in Gout: Allopurinol vs. FebuxostatCompletedNCT02579096Phase 4Results posted
• Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With GoutCompletedNCT02500641Phase 4Results posted
• Phase 2a RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedNCT02498652Phase 2Results posted
• Pharmacogenetics of SGLT2 InhibitorsTerminatedNCT02462421Phase 4Results posted
• A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With GoutCompletedNCT02287818Phase 2Results posted
• RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedNCT02279641Phase 1Results posted
• RDEA3170 and Febuxostat Combination Study in Gout SubjectsCompletedNCT02246673Phase 2Results posted
• Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.TerminatedNCT02187029Phase 1Results posted
• Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutCompletedNCT02139046Phase 3Results posted
• Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal ImpairmentCompletedNCT02128490Phase 2Results posted
• Safety and Efficacy of Oral Febuxostat in Subjects With GoutCompletedNCT02082769Phase 3Results posted
• Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic HyperuricemiaCompletedNCT02078219Phase 2Results posted
• Colchicine Or Naproxen Treatment for ACute gouTCompletedNCT01994226Phase 4Results posted
• Does Allopurinol Prolong a Treated, Acute Gout Flare?CompletedNCT01988402Phase 4Results posted
• Lesinurad and Febuxostat Combination Extension Study in GoutCompletedNCT01808144Phase 3Results posted
• A Proof-of-Concept Study of AC-201 to Prevent Gout FlaresCompletedNCT01712204Phase 2Results posted
• Open-Label Lesinurad Monotherapy Extension Study in GoutCompletedNCT01650246Phase 3Results posted
• Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and FebuxostatCompletedNCT01510769Phase 3Results posted
• Combining Lesinurad With Allopurinol in Inadequate RespondersCompletedNCT01510158Phase 3Results posted
• Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase InhibitorsCompletedNCT01508702Phase 3Results posted
• Combining Lesinurad With Allopurinol in Inadequate RespondersCompletedNCT01493531Phase 3Results posted
• Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic GoutCompletedNCT01466166Results posted
• Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout FlaresTerminatedNCT01459796Phase 3Results posted
• Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of AllopurinolCompletedNCT01451645Phase 4Results posted
• Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout PatientsCompletedNCT01399008Phase 2Results posted
• Allopurinol Outcome StudyCompletedNCT01391325Phase 4Results posted
• Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic GoutCompletedNCT01356498Phase 3Results posted
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.CompletedNCT01080131Phase 3Results posted
• Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension StudyCompletedNCT01029652Phase 3Results posted
• PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)CompletedNCT00958438Phase 3Results posted

← Gout overview